Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin’s gastric lymphoma patients

Abstract

PECAM-1, ICAM-3 and HLA-DR are representative markers of tumor expansion potential and host immune surveillance respectively. Their combined use may help us to identify high-risk patients who could benefit from more aggressive therapeutic protocols.

The cell-adhesion and signaling molecule PECAM-1 is a molecular mediator of resistance to genotoxic chemotherapy

“…22 Finally, patients whose gastric lymphomas expressed PECAM-1 have recently been shown to have significantly decreased survival compared with patients whose lymphomas do not express this molecule. 29 Taken together, these observations suggest that reducing PECAM-1 expression might be of potential therapeutic benefit by sensitizing cells to chemotherapy-induced cell death. The mechanisms by which PECAM-1 is able to exert its cytoprotective effects have been examined in only a limited number of studies.…”

An immunologist's guide to CD31 function in T-cells

“…This subpopulation of T-cells might also have an enhanced proliferative capacity, and it has been proposed that these cells enhance susceptibility to autoimmune disease (Kohler and Thiel, 2009). By contrast, the acquisition of CD31 by tumor cells provides them with resistance to apoptotic death and to immune effectors, leading to a poorer prognosis of patients Darom et al, 2006;Khattab et al, 2009;Sapino et al, 2001).…”

Review of the molecular profile and modern prognostic markers for gastric lymphoma: How do they affect clinical practice?

“…74 We have reported that HLA-DR expression in cancer cells of patients with GL is an independent factor associated with better prognosis, possibly because it induces the presentation of cancer cell antigens to Th lympocytes, thereby improving the immune response against them. 62 Patients with the HLA-DR -/ICAM-3 -phenotype have reduced 5-year survival odds compared with HLA-DR + / ICAM-3 + carriers, whereas all HLA-DR + / ICAM-3 + / PECAM-1 -carriers have 100% 5-year survival compared with 54.2% for the rest of the population. It appears that ICAM-3, PECAM-1 and HLA-DR represent complementary molecular pathways that connect the host's immune reaction to nonspecific transcellular communication and cellular migration.…”

“…62 One possible explanation is that PECAM-1 leads to the extravasation of leukocytes via its involvement in the cellular adhesion process, thus facilitating the metastasis of lymphogenic neoplasms. We also found that the PECAM-1 + /ICAM-3 -phenotype was associated with decreased 5-year survival compared with the PECAM-1 -/ ICAM-3 + phenotype.…”

“…It appears that ICAM-3, PECAM-1 and HLA-DR represent complementary molecular pathways that connect the host's immune reaction to nonspecific transcellular communication and cellular migration. 62 …”